Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer & Senior Vice President of Corporate Devel...
January 16 2018 - 07:15AM
Business Wire
Ophthotech Corporation (NASDAQ: OPHT) announced today the
election of Jane Pritchett Henderson, Chief Financial Officer and
Senior Vice President of Corporate Development at Voyager
Therapeutics, to its Board of Directors, effective immediately. Ms.
Henderson has also been elected the Chair of the Ophthotech Audit
Committee.
“We are excited to have someone of Jane’s caliber join our Board
of Directors,” stated David R. Guyer, Executive Chairman of
Ophthotech. “Jane’s financial background and corporate development
experience in life sciences is a valuable addition to the
Ophthotech board as we seek to expand our strategic vision for the
Company with our complement C5 inhibitor, Zimura®, and continue our
business development effort for both orphan diseases and larger
indications in the back of the eye, such as age-related retinal
diseases.”
“The management team at Ophthotech continues to execute on its
strategic plan and has made significant progress in restructuring
the Company, initiating and modifying multiple clinical trials of
Zimura® and continuing an aggressive business development outreach
with the goal of broadening and advancing its ophthalmic pipeline,”
stated Ms. Henderson. “I am thrilled to be joining the board at
this important time and look forward to working closely with David
Guyer, Glenn Sblendorio, other board members and the management
team.”
Jane Pritchett Henderson has more than 29 years of experience in
the life sciences industry and health care investment banking. She
currently serves as Chief Financial Officer and Senior Vice
President of Corporate Development at Voyager Therapeutics, a
publicly-traded, clinical-stage gene therapy company focused on
developing life-changing treatments for severe neurological
diseases. Prior to Voyager, Ms. Henderson served as Chief Financial
and Business Officer of Kolltan Pharmaceuticals, Inc., having
joined the privately held biopharmaceutical company in 2013 and
leading the sale of Kolltan to Celldex Pharmaceuticals, Inc. in
late 2016. Previously, Ms. Henderson served as Vice President,
Business Development of ISTA Pharmaceuticals, Inc., until ISTA
Pharmaceuticals was acquired by Bausch + Lomb. Prior to ISTA
Pharmaceuticals, Ms. Henderson served as Chief Financial Officer
and Head of Business Development at Axerion Pharmaceuticals, Inc.,
and as Chief Financial Officer and Chief Business Officer of
Panacos Pharmaceuticals, Inc. In addition to her industry
experience, Ms. Henderson’s extensive healthcare investment banking
experience includes the execution of more than 95 mergers and
acquisitions, advisory and financing deals as managing director and
other senior roles at HSBC Holdings plc, Canadian Imperial Bank of
Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson holds
a B.S. in psychology from Duke University and currently serves on
the board of directors of Eleven Biotherapeutics, Inc., a
publicly-traded biologics oncology company.
“We welcome Jane to our Board of Directors,” stated Glenn P.
Sblendorio, Chief Executive Officer and President of Ophthotech.
“We believe Jane’s extensive experience within the biotechnology
industry will provide great insight and guidance as we continue to
build this new chapter of Ophthotech.”
About Ophthotech Corporation
Ophthotech is a biopharmaceutical company specializing in the
development of novel therapeutics for age-related and orphan
diseases of the eye. For more information, please visit
www.ophthotech.com.
Forward-looking Statements
Any statements in this press release about Ophthotech’s future
expectations, plans and prospects constitute forward-looking
statements for purposes of the safe harbor provisions under the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include any statements about Ophthotech’s strategy,
future operations and future expectations and plans and prospects
for Ophthotech, and any other statements containing the words
“anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,”
“may”, “might,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions. In this press release, Ophthotech’s forward
looking statements include statements about the implementation of
its strategic plan, Ophthotech's projected use of cash and cash
balances, the timing, progress and results of clinical trials and
other development activities, and the potential for its business
development strategy, including any potential in-license or
acquisition opportunities. Such forward-looking statements involve
substantial risks and uncertainties that could cause Ophthotech’s
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, those related to the
initiation and conduct of clinical trials, availability of data
from clinical trials, expectations for regulatory matters, need for
additional financing and negotiation and consummation of in-license
and/or acquisition transactions and other factors discussed in the
“Risk Factors” section contained in the quarterly and annual
reports that Ophthotech files with the Securities and Exchange
Commission. Any forward-looking statements represent Ophthotech’s
views only as of the date of this press release. Ophthotech
anticipates that subsequent events and developments will cause its
views to change. While Ophthotech may elect to update these
forward-looking statements at some point in the future, Ophthotech
specifically disclaims any obligation to do so except as required
by law.
OPHT-G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180116005404/en/
Investors:Ophthotech CorporationKathy Galante,
212-845-8231Vice President, Investor Relations and Corporate
Communicationskathy.galante@ophthotech.comorMedia:SmithSolve
LLC on behalf of Ophthotech CorporationAlex Van Rees,
973-442-1555 ext. 111alex.vanrees@smithsolve.com
OPHTHOTECH CORP. (NASDAQ:OPHT)
Historical Stock Chart
From Feb 2024 to Mar 2024
OPHTHOTECH CORP. (NASDAQ:OPHT)
Historical Stock Chart
From Mar 2023 to Mar 2024